Liu et al. reported the that hyperactivation of the AKT/mTOR pathway is frequently observed in gliomas, and inhibiting the PI3K/AKT/mTOR pathway could enhance the sensitivity of gliomas to TMZ [26]. This evidence concerns the gene AKT1 and central nervous system cancer.